Flu

Long-lived monocyte-derived cells in the lung help sustain tissue-resident memory T cells after influenza infection, and researchers say the discovery could inform more effective nasal flu vaccines.

Investigators say the nanoparticle candidate's speedy manufacturing process and slow-mutating target could reshape how the field responds to emerging flu strains.

This study strengthens the evidence base supporting current guidelines and may help reverse the recent decline in pediatric antiviral use.

Integrated access to the state immunization registry helped a Discount Drug Mart pharmacist avoid an unnecessary pneumococcal vaccine and strengthen patient trust.

The approval clears the way for a new vaccine option for older adults ahead of the 2026-2027 flu season.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.

Morning appointments don't appear to offer any immunologic edge over afternoon ones, new data from more than 15 million patients suggest.

New data show mRNA-1010 diversifies B-cell responses well beyond what conventional hemagglutination-inhibition testing can capture.

Explore emerging flu antivirals, from season-long CD388 prevention to single-dose therapies, designed to beat current treatment limits.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

The Moderna mRNA influenza vaccine won the FDA panel vote, but ACIP turmoil and a legal fight could threaten its fall 2026 rollout.

FDA approval of the first generic version of baloxavir marboxil brings an affordable single-dose flu treatment, boosting access for the 2026-27 influenza season.

What began as a modest survey has grown into one of the most trusted barometers of frontline pharmaceutical expertise in the country.

Educate patients to help avoid duplicate acetaminophen intake and prevent interactions, and know when to consult their physician.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Dual-target flu immunity to HA and NA halves airborne spread in ferrets without escape mutations, reshaping next-generation vaccines and pharmacist counseling.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Thrifty White’s experiences provide practical lessons from designing, training, and standardizing a full-system model.

Pharmacists boost late-season flu, COVID-19, and RSV vaccination with coadministration guidance, fatigue-fighting messaging, and community access strategies.

The FDA accepts Moderna’s mRNA flu vaccine filing, targeting adults 50 years and older, with an accelerated path for older adults and a 2026 decision deadline.

The FDA declines to review Moderna’s mRNA flu vaccine filing over comparator choice, despite positive phase 3 results.

Various OTC analgesic and anesthetic products can be effective in providing prompt, temporary relief from discomfort.

Pharmacists enhance community health by offering test-and-treat services for COVID-19, influenza, strep, and RSV, improving access to care.